Literature DB >> 29873274

STAT3: a multifaceted oncoprotein.

Aleks C Guanizo1,2, Chamira Dilanka Fernando1,2, Daniel J Garama1,2, Daniel J Gough1,2.   

Abstract

Signal transducer and activator of transcription (STAT) 3 is a key signalling protein engaged by a multitude of growth factors and cytokines to elicit diverse biological outcomes including cellular growth, differentiation, and survival. The complete loss of STAT3 is not compatible with life and even partial loss of function mutations lead to debilitating pathologies like hyper IgE syndrome. Conversely, augmented STAT3 activity has been reported in as many as 50% of all human tumours. The dogma of STAT3 activity posits that it is a tyrosine phosphorylated transcription factor which modulates the expression of hundreds of genes. However, the regulation and biological consequences of STAT3 activation are far more complex. In addition to tyrosine phosphorylation, STAT3 is decorated with a plethora of post-translational modifications which regulate STAT3's nuclear function in addition to its non-genomic activities. In addition to these emerging complexities in the biochemical regulation of STAT3 activity, recent studies reveal that STAT3 is either oncogenic or a tumour suppressor. This review will explore these complexities.

Entities:  

Keywords:  STAT3; cancer; mitochondria; post-translational modifications

Mesh:

Substances:

Year:  2018        PMID: 29873274     DOI: 10.1080/08977194.2018.1473393

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  43 in total

Review 1.  Proteins moonlighting in tumor metabolism and epigenetics.

Authors:  Lei Lv; Qunying Lei
Journal:  Front Med       Date:  2021-01-02       Impact factor: 4.592

2.  The regulatory proteins DSCR6 and Ezh2 oppositely regulate Stat3 transcriptional activity in mesoderm patterning during Xenopus development.

Authors:  Mafalda Loreti; De-Li Shi; Clémence Carron
Journal:  J Biol Chem       Date:  2020-01-29       Impact factor: 5.157

Review 3.  PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.

Authors:  Sutapa Mahata; Pranab K Sahoo; Ranita Pal; Sinjini Sarkar; Tanuma Mistry; Sushmita Ghosh; Vilas D Nasare
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

4.  Elaeagnus angustifolia Plant Extract Induces Apoptosis via P53 and Signal Transducer and Activator of Transcription 3 Signaling Pathways in Triple-Negative Breast Cancer Cells.

Authors:  Arij Fouzat; Ola Jihad Hussein; Ishita Gupta; Halema F Al-Farsi; Ashraf Khalil; Ala-Eddin Al Moustafa
Journal:  Front Nutr       Date:  2022-03-18

5.  The Core Mechanism of Yiqi Yangjing Decoction Inhibiting Nonsmall-Cell Lung Cancer.

Authors:  Kaiyan Yi; Yaning Zhou; Ming Zhang; Yijun Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-09       Impact factor: 2.650

6.  Trichothecin Inhibits Cancer-Related Features in Colorectal Cancer Development by Targeting STAT3.

Authors:  Xin Qi; Meng Li; Xiao-Min Zhang; Xiu-Fen Dai; Jian Cui; De-Hai Li; Qian-Qun Gu; Zhi-Hua Lv; Jing Li
Journal:  Molecules       Date:  2020-05-14       Impact factor: 4.411

Review 7.  Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.

Authors:  Milica Nedeljković; Ana Damjanović
Journal:  Cells       Date:  2019-08-22       Impact factor: 6.600

8.  Activated STAT3 Is a Novel Regulator of the XRCC1 Promoter and Selectively Increases XRCC1 Protein Levels in Triple Negative Breast Cancer.

Authors:  Griffin Wright; Manoj Sonavane; Natalie R Gassman
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

9.  The glycoprotein GP130 governs the surface presentation of the G protein-coupled receptor APLNR.

Authors:  Kilian Trillet; Kathryn A Jacobs; Gwennan André-Grégoire; An Thys; Clément Maghe; Jonathan Cruard; Stéphane Minvielle; Sara Gonzalez Diest; Guillaume Montagnac; Nicolas Bidère; Julie Gavard
Journal:  J Cell Biol       Date:  2021-07-21       Impact factor: 10.539

10.  Rugosic acid A, derived from Rosa rugosa Thunb., is novel inhibitory agent for NF-κB and IL-6/STAT3 axis in acute lung injury model.

Authors:  Kang-Hoon Kim; Ye-Ji Park; Hyun-Jae Jang; Seung-Jae Lee; Soyoung Lee; Bong-Sik Yun; Seung Woong Lee; Mun-Chual Rho
Journal:  Phytother Res       Date:  2020-07-21       Impact factor: 6.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.